DRAX EXAMETAZIME
Peakkit for the preparation of technetium tc 99m exametazime for leukocyte labeling
NDAINTRAVENOUSPOWDER
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DRAX EXAMETAZIME (kit for the preparation of technetium tc 99m exametazime for leukocyte labeling) by Jubilant Therapeutics is radiopharmaceutical activity [moa]. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRAX EXAMETAZIME is a radiopharmaceutical kit for preparing Technetium Tc-99m labeled leukocytes used in diagnostic nuclear medicine imaging. It enables in vitro labeling of white blood cells to visualize infection, inflammation, and other leukocyte-related pathologies. The product works by binding radioactive Tc-99m to exametazime, allowing radiolabeled leukocytes to be tracked within the patient's body.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but not expanding team investment in this diagnostic imaging niche.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This radiopharmaceutical product offers career opportunities primarily in specialized sales and medical affairs focused on nuclear medicine facilities and imaging centers. Working on DRAX EXAMETAZIME suits professionals interested in diagnostic imaging commercialization within a niche, regulated specialty market.
Regional Sales Manager
Worked on DRAX EXAMETAZIME at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.